Lung cancer
Conditions
Interventions
Sponsors
Sichuan Cancer Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Provide informed consent before studying any specific procedures; 2.Primary Lung adenocarcinoma; 3.Stage IA-IIIB NSCLC; 4.Confirmed EGFRm (Ex19del/L858R) via baseline tumor biopsy sample; 5.8-week osimertinib neoadjuvant treatment; 6.Primary NSCLC deemed completely resectable by MDT evaluation including a thoracic surgeon; 7.There is NGS test result of tumor tissue before neoadjuvant treatment with osimertinib.
Exclusion criteria
Exclusion criteria: 1. Tumors with neuroendocrine components such as squamous cell carcinoma, large cell carcinoma or small cell carcinoma; 2. Exposure to other anti-tumor treatments before enrollment; 3. There are other positive driver genes such as ALK, ROS1, MET14 exon skipping, BRAF, RET, etc.; 4. Exon 20 insertion mutation in EGFR gene detection; 5. After signing the consent form, the patient and the agent request to withdraw from this clinical study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| objective response rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Pathologically significant response rate;pathological complete remission; | — |
Countries
China
Contacts
Public ContactHan Yongtao
Sichuan Cancer Hospital
Outcome results
None listed